GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » ROE % Adjusted to Book Value

I-MAB (IMAB) ROE % Adjusted to Book Value : -78.41% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB ROE % Adjusted to Book Value?

I-MAB's ROE % for the quarter that ended in Sep. 2024 was -36.07%. I-MAB's PB Ratio for the quarter that ended in Sep. 2024 was 0.46. I-MAB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -78.41%.


I-MAB ROE % Adjusted to Book Value Historical Data

The historical data trend for I-MAB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB ROE % Adjusted to Book Value Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - 6.45 -8.77 -77.95 -98.84

I-MAB Quarterly Data
Dec17 Jun18 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.74 - -175.35 73.61 -78.41

Competitive Comparison of I-MAB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, I-MAB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where I-MAB's ROE % Adjusted to Book Value falls into.



I-MAB ROE % Adjusted to Book Value Calculation

I-MAB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.27% / 0.63
=-98.84%

I-MAB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-36.07% / 0.46
=-78.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of I-MAB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB Business Description

Industry
Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).